James B. Tananbaum

Insider Reports History

Entity
Individual
Location
3052 Pacific Avenue, San Francisco, CA
Signature
/s/ James B. Tananbaum
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by James B. Tananbaum:

Stock Role Class Num Shares Value Price $ Report Date Ownership
ALUMIS INC. Director, 10%+ Owner Common Stock 4.2M $67.2M $16.00 Jul 1, 2024 Indirect
Gemini Therapeutics, Inc. /DE Director, 10%+ Owner Common Stock 412K $27.8M $67.65 Oct 4, 2021 Indirect
Quantum-Si Inc Director Class A Common Stock 4.46M $7.9M $1.77 Jun 10, 2021 Foresite Capital Fund IV, L.P.
Quantum-Si Inc Director Class A Common Stock 2.34M $4.15M $1.77 Jun 10, 2021 Foresite Capital Fund V, L.P.
Quantum-Si Inc Director Class A Common Stock 1.6M $2.83M $1.77 Jun 10, 2021 By Foresite Capital Opportunity Fund V, L.P.
Quantum-Si Inc Director Class A Common Stock 20.5K $36.3K $1.77 Jun 11, 2021 Direct
PARDES BIOSCIENCES, INC. President and CEO, Director, 10%+ Owner Common Stock 1K $1.5K $1.50 Aug 31, 2023 Indirect
Kinnate Biopharma Inc. Director, 10%+ Owner Common Stock 0 $0 $2.59 Apr 3, 2024 By Fund
Gemini Therapeutics, Inc. /DE Director, 10%+ Owner Stock Option (Right to Buy) 17.2K Oct 4, 2021 Direct
ALUMIS INC. Director, 10%+ Owner Series A Redeemable Convertible Preferred Stock 0 Jul 1, 2024 Indirect
ALUMIS INC. Director, 10%+ Owner Series B-1 Redeemable Convertible Preferred Stock 0 Jul 1, 2024 Indirect
ALUMIS INC. Director, 10%+ Owner Series B-2 Redeemable Convertible Preferred Stock 0 Jul 1, 2024 Indirect
ALUMIS INC. Director, 10%+ Owner Series C Redeemable Convertible Preferred Stock 0 Jul 1, 2024 Indirect
ALUMIS INC. Director, 10%+ Owner Series Seed Redeemable Convertible Preferred Stock 0 Jul 1, 2024 Indirect
Kinnate Biopharma Inc. Director, 10%+ Owner Stock Option (right to buy) 0 Apr 3, 2024 Direct
PARDES BIOSCIENCES, INC. President and CEO, Director, 10%+ Owner Stock Option (Right to Buy) 0 Aug 31, 2023 Direct

Insider Reports Filed by James B. Tananbaum

Symbol Company Period Transactions Value $ Form Type Date Filed Role
ALMS ALUMIS INC. Jul 1, 2024 32 $40M 4 Jul 3, 2024 Director, 10%+ Owner
ALMS ALUMIS INC. Jun 27, 2024 0 $0 3 Jun 27, 2024 Director, 10%+ Owner
KNTE Kinnate Biopharma Inc. Apr 3, 2024 5 $0 4 Apr 5, 2024 Director, 10%+ Owner
PRDS PARDES BIOSCIENCES, INC. Aug 31, 2023 5 $0 4 Aug 31, 2023 President and CEO, Director, 10%+ Owner
PRDS PARDES BIOSCIENCES, INC. Jun 1, 2023 1 $0 4 Jun 2, 2023 Director, 10%+ Owner
KNTE Kinnate Biopharma Inc. May 8, 2023 2 $4.98M 4 May 10, 2023 Director, 10%+ Owner
KNTE Kinnate Biopharma Inc. Feb 17, 2023 1 $0 4 Feb 22, 2023 Director, 10%+ Owner
KNTE Kinnate Biopharma Inc. Jun 13, 2022 1 $0 4 Jun 15, 2022 Director
PRDS PARDES BIOSCIENCES, INC. Jun 8, 2022 1 $0 4 Jun 10, 2022 Director, 10%+ Owner
PRDS PARDES BIOSCIENCES, INC. Dec 23, 2021 1 $0 4/A Jun 10, 2022 Director, 10%+ Owner
PRDS PARDES BIOSCIENCES, INC. Dec 23, 2021 2 $0 4/A Dec 30, 2021 Director, 10%+ Owner
PRDS PARDES BIOSCIENCES, INC. Dec 22, 2021 1 $3.25M 4 Dec 23, 2021 Director, 10%+ Owner
IRON Gemini Therapeutics, Inc. /DE Oct 4, 2021 1 $0 4 Oct 6, 2021 Director, 10%+ Owner
QSI Quantum-Si Inc Jun 10, 2021 7 $25M 4 Jun 14, 2021 Director
QSI Quantum-Si Inc Jun 10, 2021 0 $0 3 Jun 14, 2021 Director